Table III.
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
|
|
|||||
Factors | HR | 95% CI | P-value | HR | 95% CI | P-value |
Age, years (<68/≥68) | 5.43 | 1.42–35.40 | 0.010* | 2.58 | 0.52–18.92 | 0.252 |
Gender (male/female) | 1.96 | 0.58–8.84 | 0.288 | |||
Histological grade (poor/well-moderate) | 0.01 | 0.00–3.02 | 0.495 | |||
Tumor size, mm (≥30/<30) | 1.13 | 0.58–2.90 | 0.731 | |||
Tumor invasion (T4/Tis-3) | 2.47 | 1.39–4.54 | 0.002* | 2.21 | 1.09–5.02 | 0.026* |
Lymph node metastasis (N1–2/N0) | 6.88 | 2.04–31.12 | 0.001* | 2.07 | 0.45–10.76 | 0.342 |
Lymphatic invasion (present/absent) | 5.31 | 1.39–34.63 | 0.012* | 1.49 | 0.29–10.93 | 0.640 |
Venous invasion (present/absent) | 3.78 | 1.17–12.14 | 0.026* | 2.77 | 0.77–10.59 | 0.116 |
Distant metastasis (M1/M0) | 10.82 | 3.08–35.36 | <0.001* | 16.64 | 2.92–132.64 | 0.001* |
ANXA9 expression (high/low) | 3.00 | 1.32–12.86 | 0.004* | 3.13 | 1.30–13.69 | 0.007* |
Statistically significant.
HR, hazard ratio; CI, confidence interval; ANXA9, annexin A9.